SG10201912485PA - Vaccines for treatment and prevention of cancer - Google Patents

Vaccines for treatment and prevention of cancer

Info

Publication number
SG10201912485PA
SG10201912485PA SG10201912485PA SG10201912485PA SG10201912485PA SG 10201912485P A SG10201912485P A SG 10201912485PA SG 10201912485P A SG10201912485P A SG 10201912485PA SG 10201912485P A SG10201912485P A SG 10201912485PA SG 10201912485P A SG10201912485P A SG 10201912485PA
Authority
SG
Singapore
Prior art keywords
vaccines
cancer
prevention
treatment
Prior art date
Application number
SG10201912485PA
Other languages
English (en)
Inventor
Jennifer Buell
John Castle
Robert Stein
Daniel Levey
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of SG10201912485PA publication Critical patent/SG10201912485PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001107—Fibroblast growth factor receptors [FGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001108—Platelet-derived growth factor receptors [PDGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201912485PA 2015-05-13 2016-05-13 Vaccines for treatment and prevention of cancer SG10201912485PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562161053P 2015-05-13 2015-05-13
US201562205591P 2015-08-14 2015-08-14
US201562257458P 2015-11-19 2015-11-19
US201662307592P 2016-03-14 2016-03-14

Publications (1)

Publication Number Publication Date
SG10201912485PA true SG10201912485PA (en) 2020-02-27

Family

ID=56072474

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201912485PA SG10201912485PA (en) 2015-05-13 2016-05-13 Vaccines for treatment and prevention of cancer

Country Status (14)

Country Link
US (2) US10568948B2 (ru)
EP (1) EP3294324A1 (ru)
JP (2) JP6925980B2 (ru)
KR (1) KR20180006945A (ru)
CN (1) CN107847572A (ru)
AU (2) AU2016260540B2 (ru)
CA (1) CA2984643A1 (ru)
EA (1) EA201792501A1 (ru)
HK (1) HK1252873A1 (ru)
IL (2) IL293135A (ru)
MA (1) MA42420A (ru)
MX (2) MX2017014532A (ru)
SG (1) SG10201912485PA (ru)
WO (1) WO2016183486A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293135A (en) * 2015-05-13 2022-07-01 Agenus Inc A preparation containing at least two different complexes of purified stress protein linked to an antigenic peptide
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
SG11201810023QA (en) 2016-05-27 2018-12-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
CN109923121B (zh) 2016-11-22 2022-12-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
BR112019014593A2 (pt) 2017-01-17 2020-02-18 Heparegenix Gmbh Inibidor de mkk4 e os sais, solvatos e isômeros ópticos farmaceuticamente aceitáveis do mesmo, composto e os sais, solvatos e isômeros ópticos farmaceuticamente aceitáveis do mesmo e método de inibição seletiva da proteína quinase mkk4 em relação às proteínas quinases jnk1 e mkk7
CN110546166B (zh) 2017-04-13 2024-03-29 艾吉纳斯公司 抗cd137抗体和其使用方法
TW202402800A (zh) 2017-05-01 2024-01-16 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
KR20200003917A (ko) * 2017-05-10 2020-01-10 난토믹스, 엘엘씨 암의 검출, 예측, 및 모니터링을 위한 순환 rna(circulating rna for detection, prediction, and monitoring of cancer)
EP3694532A4 (en) 2017-10-10 2021-07-14 Gritstone Oncology, Inc. IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
EP3784688A2 (en) * 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
EP3813848A4 (en) * 2018-06-27 2022-07-20 ModernaTX, Inc. EPITOPE SELECTION FOR PERSONALIZED CANCER VACCINE
WO2020043805A1 (en) * 2018-08-28 2020-03-05 CeCaVa GmbH & Co. KG Methods for ranking and/or selecting tumor-specific neoantigens
EP3618071A1 (en) * 2018-08-28 2020-03-04 CeCaVa GmbH & Co. KG Methods for selecting tumor-specific neoantigens
CN110917341A (zh) * 2018-09-20 2020-03-27 天津贝罗尼生物科技有限公司 一种小鼠肿瘤疫苗及其制备方法
CA3111903A1 (en) * 2018-09-27 2020-04-02 Vaccibody As Method for selecting neoepitopes
CN109438570B (zh) * 2018-11-28 2021-07-20 生命谷（海南）生物科技股份有限公司 肿瘤相关基因fgfr3突变短肽及其应用
CN109517053B (zh) * 2018-11-28 2021-10-08 生命谷（海南）生物科技股份有限公司 肿瘤相关基因ret突变短肽及其应用
CN112687354B (zh) * 2019-01-29 2022-07-12 杭州纽安津生物科技有限公司 针对靶向药物PI3K、AKT、mTOR通路的激酶抑制剂的多肽疫苗组合及其设计方法
WO2020221783A1 (en) * 2019-04-29 2020-11-05 Vaccibody As Methods for pre-selection of neoepitopes
AU2020315981A1 (en) * 2019-07-24 2022-02-17 Agenus Inc. Antigenic polypeptides and methods of use thereof
EP4021486A1 (en) 2019-08-30 2022-07-06 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
CN112002374B (zh) * 2020-06-14 2022-04-22 北京臻知医学科技有限责任公司 基于深度学习的mhc-i表位亲和力预测方法
JP2023551204A (ja) * 2020-11-20 2023-12-07 シンク・セラピューティクス・インコーポレイテッド 最適化ペプチドワクチンの組成物および方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
WO2022115415A1 (en) * 2020-11-24 2022-06-02 Providence Health & Services - Oregon T cell receptors specific for a mutant form of the ret oncogene and uses thereof
CN112608992B (zh) * 2020-12-21 2022-05-10 黄志玲 一种msh6突变基因及其应用
CN113173985A (zh) * 2021-03-24 2021-07-27 深圳市新靶向生物科技有限公司 一种与结直肠癌驱动基因突变相关的抗原肽及其应用
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2024036068A1 (en) * 2022-08-12 2024-02-15 Amazon Technologies, Inc. Tumor cell identification by mapping mutations in bulk dna sequences to single cell rna sequences
WO2024054892A1 (en) * 2022-09-09 2024-03-14 Shape Therapeutics Inc. Therapeutic peptides

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4761470A (en) 1985-12-16 1988-08-02 Merck & Co., Inc. Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5137819A (en) 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
GB8915019D0 (en) 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
DE4001451A1 (de) 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
WO1993021529A1 (en) 1992-04-14 1993-10-28 Duke University Method of detecting tumors containing complexes of p53 and hsp70
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
ATE198277T1 (de) 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5496934A (en) 1993-04-14 1996-03-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acids encoding a cellulose binding domain
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2320315T5 (es) 1994-07-15 2012-12-05 University Of Iowa Research Foundation Oligonucleótidos inmunoestimuladores
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
JP4163253B2 (ja) 1995-08-18 2008-10-08 スローン−ケッタリング インスティチュート フォー キャンサー リサーチ 熱ショックタンパク質に基づくワクチンおよび免疫療法
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
CA2231998A1 (en) 1995-09-13 1997-03-20 Fordham University Therapeutic and prophylactic methods using heat shock proteins
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
DE19602985A1 (de) 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AU4502797A (en) 1996-10-01 1998-04-24 Dana-Farber Cancer Institute Immunological therapy for cancer
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
IL133912A0 (en) 1997-07-10 2001-04-30 Ctl Immunotherapies Corp A method of inducing ctl response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
CA2302522C (en) 1997-08-29 2010-08-17 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US6572860B1 (en) 1997-09-30 2003-06-03 Cel-Sci Corporation Immunogenic conjugated polypeptide for treatment of herpes simplex virus
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
WO1999022761A1 (en) 1997-10-31 1999-05-14 Sloan-Kettering Institute For Cancer Research Conjugate heat shock protein-binding peptides
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
JP2002506633A (ja) 1998-03-20 2002-03-05 ジェンザイム・コーポレーション Ｔ細胞応答を誘発するための遺伝子に基づくワクチンの組成物および使用法
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
NZ508927A (en) 1998-05-22 2003-12-19 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
DK1104306T3 (da) 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
CA2345817C (en) 1998-10-05 2013-02-12 M&E Biotech A/S Novel methods for therapeutic vaccination
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US7851591B1 (en) 1998-10-29 2010-12-14 Dana Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using universal tumor associated antigens, including hTERT
UA77152C2 (en) 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
JP2003527352A (ja) 2000-01-13 2003-09-16 アンティジェニクス インコーポレーテッド Ｃｐｇおよびサポニンの自然免疫刺激化合物、ならびにそれらの方法
US20010034042A1 (en) 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
GB0004547D0 (en) 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
US20040052812A1 (en) 2000-04-17 2004-03-18 Mee Hoe Heat shock protein-based antiviral vaccines
AU2001266694C1 (en) 2000-06-02 2005-09-01 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
WO2003015712A2 (en) 2001-08-20 2003-02-27 University Of Connecticut Health Center Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin
US20040071656A1 (en) * 2001-12-26 2004-04-15 Felix Wieland Modulation of heat-shock-protein-based immunotherapies
US7026167B2 (en) 2001-12-28 2006-04-11 University Of Virginia Patent Foundation Systems and methods for the analysis of protein phosphorylation
CA2477417A1 (en) 2002-02-28 2003-09-04 Antigenics Inc. Methods and products based on oligomerization of stress proteins
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
IL164799A0 (en) 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
JP2005533015A (ja) 2002-05-02 2005-11-04 ユニバーシティー オブ コネティカット ヘルス センター 抗体療法の有効性を増強するための熱ショックタンパク質の使用
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
EP1576124A2 (en) 2002-10-07 2005-09-21 Antigenics Inc. Heat shock protein binding fragments of cd91, and uses thereof
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
EP1601756B1 (en) 2003-02-20 2010-12-15 University of Connecticut Health Center Methods for the preparation of alpha (2) macroglobulin-antigenic molecule complexes
KR20050109498A (ko) 2003-02-20 2005-11-21 유니버시티 오브 코네티컷 헬스 센터 암 또는 전염병 치료에서 열 충격 단백질 또는알파-2-마크로글로불린을 포함하는 조성물을 사용하는 방법
US7309491B2 (en) 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
CN1816348A (zh) * 2003-04-11 2006-08-09 抗基因公司 改良的基于热休克蛋白的疫苗和免疫治疗
AU2004229458B2 (en) 2003-04-11 2009-11-19 Antigenics, Inc. Improved heat shock protein-based vaccines and immunotherapies
WO2005028496A2 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US7811828B2 (en) 2004-01-28 2010-10-12 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumuor-associated
CA2603191A1 (en) 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Cancer vaccines and therapeutic methods
BRPI0608768B1 (pt) 2005-05-09 2019-08-20 Vaxon Biotech Uso de um peptídio nativo para a produção de uma composição medicinal, processo para a obtenção in vitro de ctls com elevada avidez por um peptídio nativo e kit de vacinação
KR101562549B1 (ko) 2005-05-10 2015-10-23 인사이트 홀딩스 코포레이션 인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP1994181A4 (en) 2006-02-27 2010-05-19 Univ Arizona IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
US20090208450A1 (en) 2006-08-29 2009-08-20 Xiao-Feng Yang Method for enhancing the efficacy of antigen specific tumor immunotherapy
AT504160A1 (de) 2006-09-11 2008-03-15 Ralf Dr Kircheis Verwendung einer mehrkomponenten-tumorvakzine
CA2665816C (en) 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
CN103736086A (zh) 2007-02-15 2014-04-23 曼康公司 用于增强t细胞应答的方法
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
US8999346B2 (en) 2008-02-14 2015-04-07 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
PL2113253T3 (pl) 2008-04-30 2010-09-30 Immatics Biotechnologies Gmbh Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce
JP2009273377A (ja) 2008-05-12 2009-11-26 Igaku Seibutsugaku Kenkyusho:Kk Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法
CA2757524A1 (en) 2009-04-03 2010-10-07 Agenus Inc. Methods for preparing and using multichaperone-antigen complexes
WO2010143010A1 (en) 2009-06-09 2010-12-16 Vaxon Biotech Identification, optimization and use of shared hla-b*0702 epitopes for immunotherapy
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
JP5948319B2 (ja) 2010-05-14 2016-07-06 ザ ジェネラル ホスピタル コーポレイション 腫瘍特異的なネオ抗原を同定する組成物および方法
WO2011146828A2 (en) 2010-05-21 2011-11-24 University Of Miami Cancer treatment
EP2576614A4 (en) 2010-05-24 2013-11-13 Phosimmune Inc MHC CLASS I PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
KR102042253B1 (ko) 2010-05-25 2019-11-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ｂａｍｂａｍ：고처리율 서열분석 데이터의 병렬 비교 분석
US8340685B2 (en) 2010-08-25 2012-12-25 The Nielsen Company (Us), Llc Methods, systems and apparatus to generate market segmentation data with anonymous location data
SG191818A1 (en) 2010-12-30 2013-08-30 Foundation Medicine Inc Optimization of multigene analysis of tumor samples
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
NZ742420A (en) * 2011-05-24 2022-10-28 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Individualized vaccines for cancer
EP2752198A4 (en) 2011-08-31 2015-05-06 Univ Mie PREPARATION OF VACCINE FOR THE TREATMENT OF CANCER
WO2013158611A1 (en) 2012-04-16 2013-10-24 Agenus Inc. Methods and compositions for the treatment of glioblastomas
WO2013177593A2 (en) 2012-05-25 2013-11-28 Phosimmune, Inc. Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
KR20150021528A (ko) 2012-05-25 2015-03-02 바이엘 헬스케어 엘엘씨 펩티드의 면역원성을 예측하기 위한 시스템 및 방법
EP2869842A1 (en) * 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
AU2013289939B2 (en) 2012-07-12 2018-08-09 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
GB201214007D0 (en) 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
EP2891099A4 (en) 2012-08-28 2016-04-20 Broad Inst Inc DETECTION OF VARIANTS IN SEQUENCING DATA AND CALIBRATION
CA2883569A1 (en) 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
AU2013312529A1 (en) 2012-09-05 2015-04-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
AU2013323368B2 (en) 2012-09-28 2019-03-21 The University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
CA2894885A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
WO2014160902A1 (en) 2013-03-27 2014-10-02 Fred Hutchinson Cancer Research Center Directed immune stimulation
CA2908434C (en) 2013-04-07 2021-12-28 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US20160132631A1 (en) 2013-06-10 2016-05-12 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2015013461A2 (en) 2013-07-26 2015-01-29 Sequenta, Inc. Cancer vaccination with antigen evolution
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2015034519A1 (en) 2013-09-03 2015-03-12 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
WO2015085233A1 (en) 2013-12-06 2015-06-11 The Broad Institute Inc. Formulations for neoplasia vaccines
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
JP2017504324A (ja) 2014-01-02 2017-02-09 メモリアル スローン−ケタリング キャンサー センター 免疫療法に対する癌応答の決定因子
US20150315247A1 (en) 2014-05-04 2015-11-05 David Charles Binder High-affinity peptide-based anticancer vaccination to overcome tumor resistance to immunostimulatory antibodies and to identify TCRs that can be used successfully in adoptive T cell therapy
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
EP3191121B1 (en) 2014-09-10 2020-05-27 The University of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
WO2016040900A1 (en) 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
IL293135A (en) * 2015-05-13 2022-07-01 Agenus Inc A preparation containing at least two different complexes of purified stress protein linked to an antigenic peptide
WO2017088080A1 (es) 2015-11-25 2017-06-01 Natural Response S.A. Método para la obtención de saponinas a partir de plantas

Also Published As

Publication number Publication date
JP2018515519A (ja) 2018-06-14
AU2016260540B2 (en) 2021-01-07
JP6925980B2 (ja) 2021-08-25
EP3294324A1 (en) 2018-03-21
MX2017014532A (es) 2018-02-21
IL293135A (en) 2022-07-01
US20200237885A1 (en) 2020-07-30
EA201792501A1 (ru) 2018-10-31
IL255333A0 (en) 2017-12-31
KR20180006945A (ko) 2018-01-19
WO2016183486A1 (en) 2016-11-17
MX2022005291A (es) 2022-05-24
US20160331821A1 (en) 2016-11-17
MA42420A (fr) 2018-05-23
CA2984643A1 (en) 2016-11-17
CN107847572A (zh) 2018-03-27
AU2021202037A1 (en) 2021-04-29
US10568948B2 (en) 2020-02-25
IL255333B (en) 2022-06-01
JP2021178854A (ja) 2021-11-18
AU2016260540A1 (en) 2017-11-30
HK1252873A1 (zh) 2019-06-06

Similar Documents

Publication Publication Date Title
HK1252873A1 (zh) 用於癌症治療和預防的疫苗
IL258955A (en) Preparations and methods for the treatment of cancer
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
SI3458052T1 (sl) Kombinirano zdravljenje raka
SG11201802952TA (en) Compounds for treatment of cancer and epigenetics
IL254842B (en) Therapeutic preparations and methods for use in cancer treatment
IL263835A (en) Exosome-guided treatment of cancer
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
EP4043567C0 (en) METHOD AND COMPOSITIONS FOR TREATMENT OF CANCER
GB201413530D0 (en) Treatment and prevention of malaria
SG11201605745VA (en) Targeting clptm1l for treatment and prevention of cancer
GB201408297D0 (en) Treatment of cancer
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
GB201417456D0 (en) Treatment of cancer
GB201622214D0 (en) treatment of cancer
GB201702139D0 (en) Methods of cancer treatment
GB201703857D0 (en) Treatment of cancer
GB201702565D0 (en) Treatment of cancer
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer
GB201512723D0 (en) Treatment of cancer
GB201523012D0 (en) The combination of chinese medicine for treating infantile cough
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
GB201418640D0 (en) Agents and methods for treatment of cancer